Cantor Fitzgerald Starts Phathom Pharmaceuticals (PHAT) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts PHAT Hot Sheet
Price: $5.76 -2.54%
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Join SI Premium – FREE
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Phathom Pharmaceuticals (NASDAQ: PHAT) with a Overweight rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Phathom Pharmaceuticals click here. For more ratings news on Phathom Pharmaceuticals click here.
Shares of Phathom Pharmaceuticals closed at $5.62 yesterday.
You May Also Be Interested In
- Freedom Broker Starts MNTN Inc (MNTN) at Buy
- Stifel Starts TRex Bio (TRXB) at Buy
- Northland Starts Aureus Greenway Holdings (PUSA) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
